Pharma BD Deal Intelligence

Eli Lilly and Company / Centrexion Therapeutics, Inc. (CNTX-4975 license)

2019 · Licensing/Option · $575M · Complete

Announcement Sentiment

Strongly positive

Lilly licensed exclusive worldwide rights to CNTX-0290, a Phase 1 small molecule SSTR4 agonist for chronic pain, from Centrexion Therapeutics. Upfront $47.5M, up to $575M in development/regulatory milestones, up to $375M in sales milestones, plus tiered high-single to low-double digit royalties. Optional U.S. co-promotion election.

Key facts

Announced May 28, 2019
Deal value $575M
Deal type Licensing/Option
Therapeutic area Knee osteoarthritis pain
Indications Chronic pain
Key assets CNTX-0290
Mechanism Somatostatin receptor type 4 (SSTR4) agonist

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals